Worldwide burden of cervical cancer in 2008

Ferlay, 2004 Hakama, 1986, 1 Miller, 2002 Qiao, 2008, A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China, Lancet Oncol, 9, 929, 10.1016/S1470-2045(08)70210-9 Arbyn, 2010, HPV-based cervical cancer screening in China, Lancet Oncol, 11, 1112, 10.1016/S1470-2045(10)70262-X Munoz, 2004, Against which human papillomavirus types shall we vaccinate and screen? The international perspective, Int J Cancer, 111, 278, 10.1002/ijc.20244 Clifford, 2006, Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases, Vaccine, 24, 26, 10.1016/j.vaccine.2006.05.026 Goldie, 2008, Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries, Vaccine, 26, 4080, 10.1016/j.vaccine.2008.04.053 Andrus, 2008, Introduction of human papillomavirus vaccines into developing countries—international strategies for funding and procurement, Vaccine, 26, K87, 10.1016/j.vaccine.2008.05.003 WHO, 2008, 1 de Sanjose, 2007, Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis, Lancet Infect Dis, 7, 453, 10.1016/S1473-3099(07)70158-5 Ferlay, 2010, Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008, Int J Cancer, 10.1002/ijc.25516 Ferlay, 2010 United Nations Population Division, 2008, 10.18356/8b9a2184-en Arbyn, 2009, Trends of cervical cancer mortality in the member states of the European Union, Eur J Cancer, 45, 2640, 10.1016/j.ejca.2009.07.018 Ministry of Health of China, 2008 Pisani, 1999, Estimates of the worldwide mortality from 25 cancers in 1990, Int J Cancer, 83, 18, 10.1002/(SICI)1097-0215(19990924)83:1<18::AID-IJC5>3.0.CO;2-M Waterhouse, 1976 Kleinbaum, 1982 Arbyn, 2007, Burden of cervical cancer in Europe: estimates for 2004, Ann Oncol, 18, 1708, 10.1093/annonc/mdm079 Arbyn, 2007, Burden of cervical cancer in the 27 member states of the European Union: estimates for 2004, Ann Oncol, 18, 1425 Yang, 2004, Cervical cancer as a priority for prevention in different world regions: an evaluation using years of life lost, Int J Cancer, 109, 418, 10.1002/ijc.11719 Walboomers, 1999, Human papillomavirus is a necessary cause of invasive cervical cancer worldwide, J Pathol, 189, 12, 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F Cogliano, 2007, IARC monographs on the evaluation of carcinogenic risks to humans, Vol. 90 Bruni, 2010, Cervical HPV prevalence in five continents: meta-analysis on one million women with normal cytology, J Infect Dis, 202, 1789, 10.1086/657321 Kapeu, 2009, Is smoking an independent risk factor for invasive cervical cancer? A nested case-control study within Nordic biobanks, Am J Epidemiol, 169, 480, 10.1093/aje/kwn354 Plummer, 2003, Smoking and cervical cancer: pooled analysis of the IARC multi-centric case–control study, Cancer Causes Control, 14, 805, 10.1023/B:CACO.0000003811.98261.3e Vaccarella, 2008, Smoking and human papillomavirus infection: pooled analysis of the International Agency for Research on Cancer HPV Prevalence Surveys, Int J Epidemiol, 37, 536, 10.1093/ije/dyn033 Smith, 2002, Evidence for Chlamydia trachomatis as a human papillomavirus cofactor in the etiology of invasive cervical cancer in Brazil and the Philippines, J Infect Dis, 185, 324, 10.1086/338569 Bower, 2006, Should cervical cancer be an acquired immunodeficiency syndrome-defining cancer?, J Clin Oncol, 24, 2417, 10.1200/JCO.2005.05.4908 Gustafsson, 1997, International incidence rates of invasive cervical cancer before cytological screening, Int J Cancer, 71, 159, 10.1002/(SICI)1097-0215(19970410)71:2<159::AID-IJC6>3.0.CO;2-# Jemal, 2010, Global patterns of cancer incidence and mortality rates and trends, Cancer Epidemiol Biomarkers Prev, 19, 1893, 10.1158/1055-9965.EPI-10-0437 Jemal, 2010, Declining death rates reflect progress against cancer, PLoS One, 5, e9584, 10.1371/journal.pone.0009584 Watson, 2008, Burden of cervical cancer in the United States, 1998–2003, Cancer, 113, 2855, 10.1002/cncr.23756 Bray, 2005, Trends in cervical squamous cell carcinoma incidence in 13 European countries: changing risk and the effects of screening, Cancer Epidemiol Biomarkers Prev, 14, 677, 10.1158/1055-9965.EPI-04-0569 Cox, 1992, Projections of cervical cancer mortality and incidence in New Zealand: the possible impact of screening, J Epidemiol Community Health, 46, 373, 10.1136/jech.46.4.373 Yoshida, 2010, The relation between the cancer screening rate and the cancer mortality rate in Japan, J Med Invest, 57, 251, 10.2152/jmi.57.251 Laukkanen, 2003, Time trends in incidence and prevalence of human papillomavirus type 6, 11 and 16 infections in Finland, J Gen Virol, 84, 2105, 10.1099/vir.0.18995-0 Comber, 2004, Recent trends in cervical cancer mortality in Britain and Ireland: the case for population-based cervical cancer screening, Br J Cancer, 91, 1902, 10.1038/sj.bjc.6602236 Arbyn, 2011, Trends in cervical cancer incidence and mortality in the Baltic countries, Bulgaria and Romania, Int J Cancer, 128, 1899, 10.1002/ijc.25525 Garland, 2007, Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases, N Engl J Med, 356, 1928, 10.1056/NEJMoa061760 FUTURE II Study Group, 2007, Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions, N Engl J Med, 356, 1915, 10.1056/NEJMoa061741 Paavonen, 2009, Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women, Lancet, 374, 301, 10.1016/S0140-6736(09)61248-4 Sankaranarayanan, 2009, HPV screening for cervical cancer in rural India, N Engl J Med, 360, 1385, 10.1056/NEJMoa0808516 Arbyn, 2009, Trials comparing cytology with HPV screening, Lancet Oncol, 10, 935, 10.1016/S1470-2045(09)70296-7 Ronco, 2010, Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial, Lancet Oncol, 11, 249, 10.1016/S1470-2045(09)70360-2 Arbyn, 2010, Highlights of the 26th International Papillomavirus Conference and Workshops (Montreal, 3–8 July 2010), Future Oncol, 6, 1711, 10.2217/fon.10.136 Cuzick, 2008, Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries, Vaccine, 26, K29, 10.1016/j.vaccine.2008.06.019 WHO (Immunization, Vaccines and Biologicals), 2010